Prostacyclin and Thromboxane A2 in Platelet Vessel Wall Interactions

  • Salvador Moncada
Conference paper

Abstract

Prostacyclin was originally found as a product of the conversion of prostaglandin endoperoxides by a microsomal enzyme from blood vessels. It was described as an unstable substance which is a potent vasodilator and an inhibitor of platelet aggregation (Moncada et al. 1976a). This compound, originally called PGX (Bunting et al. 1976; Gryglewski et al. 1976; Moncada et al. 1976b), was later chemically identified by Johnson et al. (1976) as an intermediate in the formation of 6-oxo- PGF,1α compound already known (Dawson et al. 1976; Pace-Asciak 1976). PGX was then renamed prostacyclin and given the abbreviation of PGI2

Keywords

Cholesterol Dust Osteoporosis Hydrocortisone Heparin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abel RM, Buckley MJ, Austen WG, Barnett GO, Beck CH, Fischer JE (1976) Etiology, incidence and prognosis of a prospective analysis of 500 consecutive patients. J Thorac Surg 71: 323–333Google Scholar
  2. Aiken JW, Gorman RR, Shebuski RJ (1979) Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 17: 483–494PubMedCrossRefGoogle Scholar
  3. Amezcua J-L, Parsons M, Moncad S (1978) Unstable metabolites of arachidonic acid, aspirin and the formation of the haemostatic plug. Thromb Res 13: 477–488PubMedCrossRefGoogle Scholar
  4. Amezcua J-L, O’Grady J, Salmon JA, Moncad S (1979) Prolonged paradoxical effect of aspirin on platelet behaviour and bleeding time in man. Thromb Res 16: 69–79PubMedCrossRefGoogle Scholar
  5. Angelo VD, Villa S, Myskiewiec M, Donati MB, de Gaetan G (1978) Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haem 39: 535–536Google Scholar
  6. Ashida S-I, Abik Y (1978) Effect of ticlopidine and acetylsalicylic acid on generation of prostaglandin I2 like substance in rat arterial tissue. Thromb Res 13: 901–908PubMedCrossRefGoogle Scholar
  7. Baenziger NL, Dillender MJ, Majerus PW (1977) Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem Biophys Res Commun 78: 294–301PubMedCrossRefGoogle Scholar
  8. Balanowski PJP, Bauer J, Machiedo G, Neville WE (1977) Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 73: 221–224Google Scholar
  9. Bayer B-L, Blass K-E, Forste W (1979) Anti-aggregatory effect of prostacyclin (PGI2) in vivo. Br J Pharmac 66: 10–12Google Scholar
  10. Best LC, Martin TJ, Russell RGG and Preston FE (1977) Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature (Lond) 267: 850–851CrossRefGoogle Scholar
  11. Blackwell GJ, Flower RJ, Russell-Smith N, Salmon JA, Thorogood PB and Vane JR (1978) 1-n-Butylimidazole: a potent and selective inhibitor of “Thromboxane Synthetase”. Br J Pharmac 64: 436PGoogle Scholar
  12. Blajchman MA, Senyi AF, Hirsh J, Surya Y, Buchanan M and Mustard JF (1979) Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest 63: 1026–1035PubMedCrossRefGoogle Scholar
  13. Born VR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond) 194: 927–929CrossRefGoogle Scholar
  14. Branthwaite MA (1972) Neurological damage related to open heart surgery. Thorax 27: 748–753PubMedCrossRefGoogle Scholar
  15. Brooks CJW, Steel G, Gilbert JD and Harland WA (1971) Lipids of human atheroma. Part 4. Characteristics of a new group of polar sterol esters from human atherosclerotic plaques. Atherosclerosis 13: 223–237PubMedCrossRefGoogle Scholar
  16. Bunting S, Gryglewski R, Moncada S and Vane JR (1976) Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12: 897–913PubMedCrossRefGoogle Scholar
  17. Bunting S, Moncada S and Vane JR (1977) Antithrombotic properties of vascular endothelium. Lancet ii: 1075–1076CrossRefGoogle Scholar
  18. Bunting S, Moncada S, Reed P, Salmon JA and Vane JR (1978) An antiserum to 5,6-dihydro prostacyclin (PGI2) which also binds prostacyclin. Prostaglandins 15: 565–574PubMedCrossRefGoogle Scholar
  19. Bunting S, Moncada S, Vane JR, Woods HF and Weston MJ (1979) Prostacyclin improves hemocompatibility during charcoal hemoperfusion. In: Bergstrom S, Vane JR (eds) Prostacyclin. Raven Press, New York, pp 361–369Google Scholar
  20. Burch JW, Stanford N, Majerus PW (1978) Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61: 314–319PubMedCrossRefGoogle Scholar
  21. Carlson LA, Olsson AG (1976) Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet ii: 810pCrossRefGoogle Scholar
  22. Christofinis GJ, Moncada S, MacCormick C, Bunting S, Vane JR (1979) Prostacyclin (PGI2) release by rabbit aorta and human umbilical vein endothelial cells after prolonged subculture. In: Vane JR, Bergstrom S (eds) Prostacyclin. Raven Press, New York, pp 77–84Google Scholar
  23. Coppe D, Wonders T, Snider M, Salzman EW (1979) Preservation of platelet number and function during extracorporeal membrane oxygenation (ECMO) by regional infusion of prostacyclin. In: Vane JR, Bergstrom S (eds) Prostacyclin. Raven Press, New York, pp 371–383Google Scholar
  24. Czervionke RL, Hoak JC, Fry GL (1978) Effect of aspirin on thrombin-induced adherence of platelets to cultured cells from the blood vessel walls. J Clin Invest 62: 847–856PubMedCrossRefGoogle Scholar
  25. Czervionke RL, Smith JB, Fry GL, Hoak JC (1979) Inhibition of prostacyclin by treatment of endothelium with aspirin. J Clin Invest 63: 1089–1092PubMedCrossRefGoogle Scholar
  26. Davison EM, Ford-Hutchinson AW, Smith MJH, Walker JR (1978) The release of thromboxane B2 by rabbit peritoneal polymorphonuclear leukocytes. Br J Pharmac 63: 407pGoogle Scholar
  27. Dawson W, Boot JR, Cockerill AF, Mallen DNB, Osborne DJ (1976) Release of novel prostaglandins and thromboxanes after immunological challenge of guinea pig lung. Nature (Lond) 262: 699–702CrossRefGoogle Scholar
  28. Dembinska-Kiec A, Gryglewska T, Zmuda A, Gryglewski RJ (1977) The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbit. Prostaglandins 14: 1025–1034PubMedCrossRefGoogle Scholar
  29. Dusting GJ, Moncada S, Vane JR (1977) Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. Prostaglandins 13: 3–15PubMedCrossRefGoogle Scholar
  30. Dusting GJ, Moncada S, Vane JR (1978) Recirculation of prostacyclin (PGI2) in the dog. Br J Pharmac 64: 315–320Google Scholar
  31. Dyerberg J, Bang HO (1979) Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet ii: 433–435CrossRefGoogle Scholar
  32. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR (1978) Polyunsaturated fatty acids, atherosclerosis and thrombosis. Lancet ii: 117–119CrossRefGoogle Scholar
  33. Eakins KE, Rajadhyaksha V, Schroe R (1976) Prostaglandin antagonism by sodium p-benzyl-4-(l-oxo-2(4-chlorobenzyl)-3-phenylpropyl) phenyl phosphonate (N-0164). Br J Pharmac 58: 333–339Google Scholar
  34. Flower RJ (1978) Steroidal anti-inflammatory drugs as inhibitors of phospholipase A2. In: Paoletti R, Samuelsson B (eds) Advances in Prostaglandin and Thromboxane Research, Academic Press, New York, Vol. 3 pp 105–112Google Scholar
  35. Fukazum K (1965) Lipids of the atherosclerotic artery. HI A hypothesis on the cause of atherosclerosis from the viewpoint of fat chemistry. Yukagaku 14: 119–122Google Scholar
  36. Fukazumi K, Iwat Y (1963) Lipids of atherosclerotic artery. II. Dialysis of lipids of abdominal aorta and lipids in lipid protein complexes existing in the aorta. Yukagaku 12: 93–97Google Scholar
  37. Glavind J, Hartmann S, Clemmesen J, Jessen KE, Da H (1952) Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathol Microbiol Scand 30: 1PubMedCrossRefGoogle Scholar
  38. Godal HC, Eika C, Dybdahl JH, Daae L, Larse S (1979) Aspirin and bleeding time. Lancet i: 1236CrossRefGoogle Scholar
  39. Goldstein IM, Malmsten CL, Kaplan HB, Kindahl H, Samuelsson B and Weissma G (1977) Thromboxane generation by stimulated human granulocytes: Inhibition by glucocorticoids and Superoxide dismutase. Clin Res 25: 518AGoogle Scholar
  40. Gordon JL, Pearson JD (1978) Effects of sulphinpyrazone and aspirin on prostaglandin I2 (prostacyclin) synthesis by endothelial cells. Br J Pharmac 64: 481–483Google Scholar
  41. Gorman RR, Bunting S, Miller OV (1977) Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13: 377–388PubMedCrossRefGoogle Scholar
  42. Gorman RR, Hamilton RD, Hopkins NK (1979) Stimulation of human foreskin fibroblast adenosine 3′: 5′-cyclic monophosphate levels by prostacyclin (prostaglandin I2. J Biol Chem 254: 1671–1676PubMedGoogle Scholar
  43. Griffith GC, Nichols G, Asher JD, Flanaga B (1965) Heparin osteoporosis. J Am Med Ass 193: 91–94CrossRefGoogle Scholar
  44. Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR (1976) Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12: 685–714PubMedCrossRefGoogle Scholar
  45. Gryglewski RJ, Korbut R, Ocetkiewicz, AC (1978a) Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature (Lond) 273: 765–767CrossRefGoogle Scholar
  46. Gryglewski RJ, Korbut R, Ocetkiewicz AC (1978b) De-aggregatory action of prostacyclin in vivo and its enhancement by theophylline. Prostaglandins 15: 637–644PubMedCrossRefGoogle Scholar
  47. Ham EA, Egan RW, Soderman DD, Gale PH, Kuehl FA Jr (1979) Peroxidase-dependent deactivation of prostacyclin synthetase. J Biol Chem 254: 2191–2194PubMedGoogle Scholar
  48. Harker LA, Joy N, Wall RT, Quadracci L, Strike G (1977) Inhibition of platelet reactivity by endothelial cells. Thromb Haem (Abstract) 38: 137Google Scholar
  49. Harker LA, Slichter SJ (1972) Platelet and fibrinogen consumption in man. N Eng J Med 287: 999–1005CrossRefGoogle Scholar
  50. Harland WA, Gilbert JD, Steel G, Brooks JW (1971) Lipids of human atheroma. Part 5. The occurrence of a new group of polar sterol esters in various stages of human atherosclerosis. Atherosclerosis 13: 239–246PubMedCrossRefGoogle Scholar
  51. Harman D, Piette LH (1966) Free radical theory of ageing: free radical reaction in serum. J Gerontol 21: 560–565PubMedGoogle Scholar
  52. Harrison HE, Reece AH, Johnso M (1978) Decreased vascular prostacyclin in experimental diabetes. Life Sci 23: 351–356PubMedCrossRefGoogle Scholar
  53. Hawkins HJ, Smith BJ, Nicolaou KC, Eling TE (1978) Studies of the mechanisms involved in the fate of prostacyclin (PGI2)nd 6-keto-PGF1αin the pulmonary circulation. Prostaglandins 16: 871–884CrossRefGoogle Scholar
  54. Heyns AduP, van den Berg, DJ, Potgieter GM, Retief FP (1974) The inhibition of platelet aggregation by an aorta intima extract. Thromb Diath Haemorrh 32: 417–431PubMedGoogle Scholar
  55. Higgs EA, Moncada S, Vane JR, Caen JP, Michel H, Tobele G (1978a) Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins 16: 17–22PubMedCrossRefGoogle Scholar
  56. Higgs GA, Bunting S, Moncada S, Vane JR (1976) Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins 12: 749–757PubMedCrossRefGoogle Scholar
  57. Higgs GA, Moncada S, Vane JR (1977) Prostacyclin (PGI2 inhibits the formation of platelet thrombi induced by adenosine diphosphate (ADP) in vivo. Br J Pharmac 61: 137pGoogle Scholar
  58. Higgs GA, Moncada S, Vane JR (1978b) Prostacyclin (PGI2) reduces the number of “slow moving” leukocytes in hamster cheek pouch venules. J Physiol 280: 55–56PGoogle Scholar
  59. Honour AJ, Hockaday TDR, Mann JI (1977) The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels. Br J Exp Path 58: 268–272Google Scholar
  60. Hopkins NK, Sun FF, Gorman RR (1978) Thromboxane A2 biosynthesis in human lung fibroblasts, Wl-38. Biochem Biophys Res Commun 85: 827–836PubMedCrossRefGoogle Scholar
  61. Hornstra G, Haddeman E, Don JA (1979) Blood platelets do not provide endoperoxides for vascular prostacyclin production. Nature 279: 66–68PubMedCrossRefGoogle Scholar
  62. Iwakam M (1965) Peroxides as a factor of atherosclerosis. Nagoya J Med Sci 28: 50–66Google Scholar
  63. Johnson M, Reece AH, Harrison HE (1979) Decreased vascular prostacyclin in experimental diabetes. Advances in Pharmacology & Therapeutics 4: 865pGoogle Scholar
  64. Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR (1976) The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 12: 915–928PubMedCrossRefGoogle Scholar
  65. Jorgensen KA, Olesen AS, Dyerberg J, Stofferse E (1979) Aspirin and bleeding time: Dependency of Age. Lancet ii: 302CrossRefGoogle Scholar
  66. Kazer-Glanzman R, Jakabova M, George J, Lusche E (1977) Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3′,5′-cyclic monophosphate and protein kinase. Biochim Biophys Acta 466: 429–440CrossRefGoogle Scholar
  67. Kelton JG, Hirsch J, Carter CJ, Buchanan MR (1978) Thrombogenic effect of high dose aspirin in rabbits; relationship to inhibition of vessel wall synthesis of prostaglandin I2 like activity. J Clin Invest 62: 892–895PubMedCrossRefGoogle Scholar
  68. Korbut R, Moncad S (1978) Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy. Thromb Res 13: 489–500PubMedCrossRefGoogle Scholar
  69. Lagarde M, Dechavanne M (1977) Increase of platelet prostaglandin cyclic endoperoxides in thrombosis. Lancet i: 88CrossRefGoogle Scholar
  70. Lapetina EG, Schmitges CJ, Chandrabose K, Cuatrecasa P (1977) Cyclic adenosine 3′,5′-monophosphate and prostacyclin inhibit membrane phospholipase activity in platelets. Biochem Biophys Res Commun 76: 828–835PubMedCrossRefGoogle Scholar
  71. Lieberman GE, Lewis GP, Peters TJ (1977) A membrane-bound enzyme in rabbit aorta capable of inhibiting adenosine-diphosphate-induced platelet aggregation. Lancet ii: 330–332CrossRefGoogle Scholar
  72. Longmore DB, Bennett G, Gueirrara D, Smith M, Bunting S, Reed P, Moncada S, Read NG, Vane JR (1979) Prostacyclin: A solution to some problems of extracorporeal circulation. Lancet i: 1002–1005CrossRefGoogle Scholar
  73. Maclntyre DE, Pearson JD, Gordon JL (1978) Localisation and stimulation of prostacyclin production in vascular cells. Nature 271: 549–551CrossRefGoogle Scholar
  74. Main IHM, Whittle JR (1975) Potency and selectivity of methyl analogues of prostaglandin E2 on rat gastrointestinal function. Br J Pharmac 54: 309–317Google Scholar
  75. Majerus PW (1976) Why aspirin? Circulation 54: 357–359PubMedGoogle Scholar
  76. Malmsten C, Granstrom E, Samuelsso B (1976) Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets. Biochem Biophys Res Commun 68: 569–576PubMedCrossRefGoogle Scholar
  77. Marcus AJ (1978) The role of lipids in platelet function with particular reference to the arachidonic acid pathway. J Lipid Res 19: 793–826PubMedGoogle Scholar
  78. Marcus AJ, Weksler BB, Jaffe EA (1978) Enzymatic conversion of prostaglandin endoperoxide H2 and arachidonic acid to prostacyclin by cultured human endothelial cells J Biol Chem 253: 7138–7141PubMedGoogle Scholar
  79. Miller OV, Gorman RR (1979) Evidence for distinct PGI2 and PGD2 receptors in human platelets. J Pharm Exp Ther, in pressGoogle Scholar
  80. Minkes M, Stanford M, Chi M, Roth G, Raz A, Needleman P, Majeru P (1977) Cyclic adenosine 3,′5′-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. J Clin Invest 59: 449–454PubMedCrossRefGoogle Scholar
  81. Moncada S, Korbu R (1978) Dipyridamole and other phosphodiesterase inhibitors act as anti-thrombotic agents through potentiating endogenous prostacyclin. Lancet i: 1286–1289CrossRefGoogle Scholar
  82. Moncada S, Vane JR (1977) The discovery of prostacyclin — a fresh insight into arachidonic acid metabolism. In: Kharasch N, Fried J (eds), Academic Press, New York, San Francisco, London, pp 155–177Google Scholar
  83. Moncada S, Vane JR (1978) Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 34: 129–135PubMedGoogle Scholar
  84. Moncada S, Vane JR (1979) Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. New Eng J Med 300: 1142–11PubMedCrossRefGoogle Scholar
  85. Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976a) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (Lond) 263: 663–665CrossRefGoogle Scholar
  86. Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976b) A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (Prostaglandin X) which prevents platelet aggregation. Prostaglandins 12: 715–733PubMedCrossRefGoogle Scholar
  87. Moncada S, Higgs EA, Vane JR, (1977a) Human arterial and venous tissues generate prostacyclin (prostaglandin X) a potent inhibitor of platelet aggregation. Lancet 1: 18–21PubMedCrossRefGoogle Scholar
  88. Moncada S, Herman AG, Higgs EA, Vane JR (1977b) Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 11: 323–344PubMedCrossRefGoogle Scholar
  89. Moncada S, Korbut R, Bunting S, Vane JR (1978) Prostacyclin is a circulating hormone. Nature (Lond) 273: 767–768CrossRefGoogle Scholar
  90. Mullane KM, Moncada S, Vane JR (1979) Prostacyclin release induced by bradykinin may contribute to the anti-hypertensive action of angiotensin converting enzyme inhibitors. 4th Int Prost Cong, Washington, Raven Press, New York, inpressGoogle Scholar
  91. Nafsta I (1974) Endothelial damage and platelet thrombosis associated with PUFA-rich, vitamin E deficient diet fed to pig. Thromb Res 5: 25Google Scholar
  92. Needleman P, Bronson, SD, Wyche A, Sivakoff M, Nicolaou KC (1978) Cardiac and renal prostaglandin I2. J Clin Invest 61: 839–849PubMedCrossRefGoogle Scholar
  93. Needleman P, Wyche A, Ra A (1979) Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest 63: 345–349PubMedCrossRefGoogle Scholar
  94. Nijkamp FP, Moncada S, White HL, Vane JR (1977) Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmac 44: 179–187CrossRefGoogle Scholar
  95. Nordoy A, Svensson B, Hoak JC (1978a) The inhibitory effect of human endothelial cell monolayers on platelet reactions and its inhibition by aspirin. Thromb Res 12: 597–608PubMedCrossRefGoogle Scholar
  96. Nordoy A, Svensson B, Wiebe D, Hoak JC (1978b) Lipoproteins and the inhibitory effect of human endothelial cells on platelet function. Circ Res 43: 527–534PubMedGoogle Scholar
  97. O’Grady J, Moncad S (1978) Aspirin: A paradoxical effect on bleeding time. Lancet ii: 780CrossRefGoogle Scholar
  98. Pace-Ascia C (1976) Isolation, structure and biosynthesis of 6-keto prostaglandin F,1α in the rat stomach. J Am Chem Soc 98: 2348–2349CrossRefGoogle Scholar
  99. Pace-Atciak CR, Carrara MC, Rangaraj G, Nicolaou KG (1978) Enhanced formation of PGI2, a potent hypotensive substance, by aortic rings and homogenates of the spontaneously hypertensive rat. Prostaglandins 15: 1005–1012CrossRefGoogle Scholar
  100. Rajah SM, Penny S, Keste R (1978) Aspirin and bleeding time. Lancet ii: 1104CrossRefGoogle Scholar
  101. Raz A, Minkes MS, Needlema P (1977) Endoperoxides and thromboxanes. Structural determinants for platelet aggregation and vasoconstriction. Biochim Biophys Acta 488: 305–311PubMedGoogle Scholar
  102. Remuzzi G, Cavenaghi AE, Mecca G, Donati MB, de Gaetan G (1977) Prostacyclin (PGI2) and bleeding time in uremic patients. Thromb Res 11: 919–920PubMedCrossRefGoogle Scholar
  103. Remuzzi G, Misiani R, Marchesi D, Livio M, Mecca G, de Gaetano G, Donati MB (1978) Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity. Lancet ii: 871–872CrossRefGoogle Scholar
  104. Robert A, Hanchar AJ, Lancaster C, Nezamis JE (1979) Prostacyclin inhibits enteropooling and diarrhea. In: Vane JR, Bergstrom S (eds) Prostacyclin, Raven Press, New York, pp 147–158Google Scholar
  105. Rosenblum WI, El-Sabba F (1978) Enhancement of platelet aggregation by tranylcyprominne in mouse cerebral microvessels. Circ Res 43: 238–241PubMedGoogle Scholar
  106. Roth GJ, Majerus PW (1975) The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particular fraction protein. J Clin Invest 56: 624–632PubMedCrossRefGoogle Scholar
  107. Roth GJ, Siok CJ (1978) Acetylation of the NH2terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 253: 3782–3784PubMedGoogle Scholar
  108. Saba SR, Mason RG (1974) Studies of an activity from endothelial cells that inhibits platelet aggregation, serotonin release and clot retraction. Thromb Res 5: 747–757PubMedCrossRefGoogle Scholar
  109. Salmon JA, Smith DR, Flower RJ, Moncada S, Vane JR (1978) Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta 523: 250–262PubMedGoogle Scholar
  110. Sanders TAB, Ellis FR, Dickerson WT (1977) Polyunsaturated fatty acids and the brain. Lancet i: 751CrossRefGoogle Scholar
  111. Shimamoto T, Kobayashi M, Takahashi T, Takashima Y, Sakamoto M, Morook S (1978) An observation of thromboxane A2 in arterial blood after cholesterol feeding in rabbits. Jap Heart J 19: 748–757PubMedCrossRefGoogle Scholar
  112. Sinzinger H, Feigl W, Silberbaue K (1979) Prostacyclin generation in atherosclerotic arteries. Lancet ii: 469CrossRefGoogle Scholar
  113. Slater TF (1972) Free radical mechanisms in tissue injury. Pion Ltd., LondonGoogle Scholar
  114. Szczeklik A, Gryglewski RJ, Nizankowski R, Musial J, Pieton R, Mru J (1978a) Circulatory and antiplatelet effects of intravenous prostacyclin in healthy man. Pharm Res Commun 10: 545–556CrossRefGoogle Scholar
  115. Szczeklik A, Gryglewski RJ, Musial J, Grodzinska L, Serwonska M, Marcinkiewic E (1978b) Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haem 40: 66–74Google Scholar
  116. Szczeklik A, Nizankowski R, Skawinski S, Szczeklik J, Gluszko P, Gryglewski RJ (1979) Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet i: 1111–1114CrossRefGoogle Scholar
  117. Tansik RL, Namm DH, White HL (1978) Synthesis of prostaglandin 6-keto F1α by cultured aortic smooth muscle cells and stimulation of its formation in a coupled system with platelet lysates. Prostaglandins 15: 399–408PubMedCrossRefGoogle Scholar
  118. Tateson JE, Moncada S, Vane JR (1977) Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 13: 389–399PubMedCrossRefGoogle Scholar
  119. Ubatuba FB, Moncada S, Vane JR (1979) The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time. Thromb Haem 41: 425–434Google Scholar
  120. Vargaftig BB, Chignar M (1975) Substancces that increase the cyclic AMP content prevent platelet aggregation and concurrent release of pharmacologically active substances evoked by arachidonic acid. Agents and Actions 5: 137–144PubMedCrossRefGoogle Scholar
  121. Vermylen J, Chamone DAF, Verstraet M (1979) Stimulation of prostacyclin release from vessel wall by BAYg6575, an antithrombotic compound. Lancet i: 518–520CrossRefGoogle Scholar
  122. Von Lossonczy TO, Ruiter A, Bronsgeest-Schoute HC, van Gent CM, Hermus, JJ (1978) The effect of a fish diet on serum lipids in healthy human subjects. Am J Clin Nutr 31: 1340Google Scholar
  123. Weihrauch JL, Brignoli CA, Reeves JB, Iverson JL (1977) Fatty acid composition of margarines, processed fats and oils. Food Technology 31: 80Google Scholar
  124. Weiss HJ, Turitto VT (1979) Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 53: 244–250PubMedGoogle Scholar
  125. Weiss SJ, Turk J, Needlema P (1979) A mechanism for the hydroperoxide-mediated inactivation of prostacyclin synthetase. Blood 53: 1191–1196PubMedGoogle Scholar
  126. Weksler BB, Marcus AJ, Jaffe EA (1977a) Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acaa Sci USA 74: 3922–3926CrossRefGoogle Scholar
  127. Weksler BB, Knapp JM, Jaffe EA (1977b) Prostacyclin (PGI2) synthesized by cultured endothelial cells modulates polymorphonuclear leukocyte function. Blood 50(5): Suppl 1. p 287Google Scholar
  128. Whittle BJR, Moncada S, Vane JR (1978) Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prosfaglandins 16: 373–388CrossRefGoogle Scholar
  129. Williams KI, Downing II (1977) Prostaglandin and thromboxane production by rat decidual microsomes. Prostaglandins 14: 813–817PubMedCrossRefGoogle Scholar
  130. Woodford FP, Bottcher, CJF, Oette K, Ahrens EH Jr. (1965) The artifactual nature of lipid peroxides detected in extracts of human aorta. J Atheroscler Res 5: 311–316PubMedCrossRefGoogle Scholar
  131. Woods HF, Ash G, Weston MJ, Bunting S, Moncada S, Vane JR (1978) Prostacyclin can replace heparin in haemodialysis in dogs. Lancet ii: 1075–1077CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1980

Authors and Affiliations

  • Salvador Moncada

There are no affiliations available

Personalised recommendations